Recently, immunotherapy using immune checkpoint-blocking antibodies targeting programmed death 1/programmed death ligand 1 (PD-1/PD-L1) has improved the outcomes for patients with a variety of malignant tumors (4, 5). The gene discussed is CD274; the disease is cancer.